{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:00:20Z","timestamp":1790791220454,"version":"4.1.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T00:00:00Z","timestamp":1777161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Limited data exist on whether the benefits of elexacaftor\/tezacaftor\/ivacaftor (ETI) seen in randomized controlled trials are sustained in clinical practice in people with cystic fibrosis (PwCF) taking ETI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study evaluated the longitudinal effect of ETI on lung function and nutritional outcomes in clinical practice and analyzed the heterogeneity of response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PwCF\u2009\u2265\u200912\u2009years with at least one copy of F508del who were enrolled in the CF Foundation Patient Registry (CFFPR) between 2018 and 2022 with documented ETI prescription were included. Mean percent predicted forced expiratory volume in 1\u2009second (ppFEV1) and body mass index (BMI) were examined for 1\u2009year preceding and 3\u2009years following ETI initiation. We used linear regression with generalized estimating equations (GEE) to evaluate longitudinal changes. We compared characteristics of participants who had a clinically meaningful response for both ppFEV1 and BMI to participants with neither a ppFEV1 nor BMI response. We used a negative binomial model to evaluate pulmonary exacerbation (PEx) rates and accounted for effects of viral respiratory trends.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements and main results<\/jats:title>\n                    <jats:p>Among 11\u00a0151 PwCF included in the ppFEV1 analysis, we found a mean ppFEV1 increase of 9.9 (95% CI 9.6-10.2) between the pre- and post-ETI initiation periods over 3\u00a0years. Mean BMI increased by 1.03\u2009kg\/m2 (95% CI 0.98-1.07) in the 3\u2009years post-ETI initiation among 12\u00a0119 PwCF in the BMI analysis. Among participants with both ppFEV1 and BMI data, 3594 (32.8%) experienced significant improvement in both ppFEV1 and BMI. Participants with both ppFEV1 and BMI improvement were more likely to have had a PEx prior to ETI initiation, history of Pseudomonas aeruginosa infection, pancreatic insufficiency, CF-related diabetes, and lower BMI pre-ETI. PEx rates were significantly reduced post-ETI initiation, even after adjusting for peak respiratory virus periods (unadjusted incidence rate ratio (IRR) (95% CI) 0.26 (0.25-0.27), adjusted IRR 0.62 (0.57-0.66)).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This effectiveness analysis of observational data from the CFFPR found sustained improvements in lung function and nutritional status for 3\u00a0years following ETI initiation. Only 32% had an improvement in both FEV1 and BMI, indicating that not all PwCF respond uniformly to ETI therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/annalsats\/aaoag095","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T18:39:49Z","timestamp":1777142389000},"page":"1466-1475","source":"Crossref","is-referenced-by-count":0,"title":["Clinical effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis in the United States"],"prefix":"10.1093","volume":"23","author":[{"given":"Georgene E","family":"Hergenroeder","sequence":"first","affiliation":[{"name":"Children\u2019s Hospital of Philadelphia Division of Pulmonary and Sleep Medicine, Department of Pediatrics, , Philadelphia, PA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan V","family":"Todd","sequence":"additional","affiliation":[{"name":"Cystic Fibrosis Foundation , Bethesda, MD,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josh S","family":"Ostrenga","sequence":"additional","affiliation":[{"name":"Cystic Fibrosis Foundation , Bethesda, MD,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher H","family":"Goss","sequence":"additional","affiliation":[{"name":"University of Washington Division of Pulmonary, Critical Care and Sleep Medicine, , Seattle, WA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2407-7374","authenticated-orcid":false,"given":"Raksha","family":"Jain","sequence":"additional","affiliation":[{"name":"University of Texas Southwestern Medical Center Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, , Dallas, TX,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne","family":"Morgan","sequence":"additional","affiliation":[{"name":"The University of Arizona Pediatric Pulmonary and Sleep Medicine, Department of Pediatrics, , Tucson, AZ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3356-709X","authenticated-orcid":false,"given":"Gregory S","family":"Sawicki","sequence":"additional","affiliation":[{"name":"Boston Children\u2019s Hospital Department of Pulmonary Medicine, , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S","family":"Schechter","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital of Richmond at Virginia Commonwealth University Division of Pulmonary Medicine, Department of Pediatrics, , Richmond, VA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhonda","family":"Szczesniak","sequence":"additional","affiliation":[{"name":"Cincinnati Children\u2019s Hospital Medical Center and University of Cincinnati Division of Biostatistics and Epidemiology, , Cincinnati, OH,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A","family":"Cromwell","sequence":"additional","affiliation":[{"name":"Cystic Fibrosis Foundation , Bethesda, MD,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clement L","family":"Ren","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital of Philadelphia Division of Pulmonary and Sleep Medicine, Department of Pediatrics, , Philadelphia, PA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,26]]},"reference":[{"key":"2026093013535453600_aaoag095-B1","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1056\/NEJMra2216474","article-title":"Cystic fibrosis","volume":"389","author":"Grasemann","year":"2023","journal-title":"N Engl J Med"},{"key":"2026093013535453600_aaoag095-B2","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/S0140-6736(23)01609-4","article-title":"CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis","volume":"402","author":"Taylor-Cousar","year":"2023","journal-title":"Lancet"},{"key":"2026093013535453600_aaoag095-B3","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","article-title":"VX-445-tezacaftor-ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles","volume":"379","author":"Keating","year":"2018","journal-title":"N Engl J Med"},{"key":"2026093013535453600_aaoag095-B4","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"2026093013535453600_aaoag095-B5","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"2026093013535453600_aaoag095-B6","author":"Cystic Fibrosis Foundation Patient Registry"},{"key":"2026093013535453600_aaoag095-B7","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.jcf.2018.03.001","article-title":"Cystic fibrosis patient registries: a valuable source for clinical research","volume":"17","author":"Dasenbrook","year":"2018","journal-title":"J Cyst Fibros"},{"key":"2026093013535453600_aaoag095-B8","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: a clinical trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026093013535453600_aaoag095-B9","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.jcf.2023.03.002","article-title":"Real-world safety and effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: interim results of a long-term registry-based study","volume":"22","author":"Bower","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2026093013535453600_aaoag095-B10","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.jcf.2022.12.009","article-title":"Effect of elexacaftor\/tezacaftor\/ivacaftor on annual rate of lung function decline in people with cystic fibrosis","volume":"22","author":"Lee","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2026093013535453600_aaoag095-B11","doi-asserted-by":"publisher","first-page":"100690","DOI":"10.1016\/j.lanepe.2023.100690","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis: real-world evidence from the German CF Registry","volume":"32","author":"Sutharsan","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"2026093013535453600_aaoag095-B12","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13154491","article-title":"CFTR modulators therapy efficacy in reducing cystic fibrosis (CF) exacerbation and improving selected spirometry parameters: a real-life study in a single-centre polish population","volume":"13","author":"Winiarska","year":"2024","journal-title":"J Clin Med"},{"key":"2026093013535453600_aaoag095-B13","doi-asserted-by":"publisher","first-page":"00339","DOI":"10.1183\/23120541.00339-2024","article-title":"Lung function improvement on triple modulators: high-resolution, nationwide data from the Danish Cystic Fibrosis Cohort","volume":"10","author":"Leo-Hansen","year":"2024","journal-title":"ERJ Open Res"},{"key":"2026093013535453600_aaoag095-B14","doi-asserted-by":"publisher","first-page":"S391","DOI":"10.1016\/S1569-1993(24)01536-4","article-title":"698 real-world impact of elexacaftor\/tezacaftor\/ivacaftor on pulmonary and nutritional outcomes in people with cystic fibrosis","volume":"23","author":"Hergenroeder","year":"2024","journal-title":"J Cyst Fibros"},{"key":"2026093013535453600_aaoag095-B15","author":"Hergenroeder","year":"2024"},{"key":"2026093013535453600_aaoag095-B16","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1513\/AnnalsATS.201511-781OC","article-title":"The cystic fibrosis foundation patient registry. Design and methods of a National Observational Disease Registry","volume":"13","author":"Knapp","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"2026093013535453600_aaoag095-B17","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.jcf.2024.03.013","article-title":"The impact of switching to race-neutral reference equations on FEV(1) percent predicted among people with cystic fibrosis","volume":"23","author":"Rosenfeld","year":"2024","journal-title":"J Cyst Fibros"},{"key":"2026093013535453600_aaoag095-B18","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.jcf.2022.03.010","article-title":"Obesity in cystic fibrosis: prevalence, trends and associated factors data from the US Cystic Fibrosis Foundation Patient registry","volume":"21","author":"Szentpetery","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2026093013535453600_aaoag095-B19","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1513\/AnnalsATS.202209-829OC","article-title":"Lung function decline in cystic fibrosis: impact of data availability and modeling strategies on clinical interpretations","volume":"20","author":"Szczesniak","year":"2023","journal-title":"Ann Am Thorac Soc"},{"key":"2026093013535453600_aaoag095-B20","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s41579-022-00807-9","article-title":"The effects of the COVID-19 pandemic on community respiratory virus activity","volume":"21","author":"Chow","year":"2023","journal-title":"Nat Rev Microbiol"},{"key":"2026093013535453600_aaoag095-B21","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jcf.2024.10.006","article-title":"Factors associated with prescription of elexacaftor\/tezacaftor\/ivacaftor among people with cystic fibrosis aged 12 years or older with at least one F508del allele","volume":"24","author":"Hergenroeder","year":"2025","journal-title":"J Cyst Fibros"},{"key":"2026093013535453600_aaoag095-B22","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1002\/ppul.20858","article-title":"Dornase alfa and progression of lung disease in cystic fibrosis","volume":"43","author":"Konstan","year":"2008","journal-title":"Pediatr Pulmonol"},{"key":"2026093013535453600_aaoag095-B23","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.jada.2008.02.020","article-title":"Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review","volume":"108","author":"Stallings","year":"2008","journal-title":"J Am Diet Assoc"},{"key":"2026093013535453600_aaoag095-B24","doi-asserted-by":"publisher","first-page":"872","DOI":"10.3945\/ajcn.112.051409","article-title":"Longitudinal trends in nutritional status and the relation between lung function and BMI in cystic fibrosis: a population-based cohort study","volume":"97","author":"Stephenson","year":"2013","journal-title":"Am J Clin Nutr"},{"key":"2026093013535453600_aaoag095-B25","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.jcf.2023.05.010","article-title":"Nutritional considerations for a new era: a CF foundation position paper","volume":"22","author":"Leonard","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2026093013535453600_aaoag095-B26","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/S2213-2600(22)00434-9","article-title":"Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials","volume":"11","author":"Mayer-Hamblett","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2026093013535453600_aaoag095-B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.chpulm.2024.100080","article-title":"Using real-world research to study the impact of chronic daily therapy discontinuation in cystic fibrosis: the home reported outcomes in cystic fibrosis 2 (HERO-2) study design","author":"Rosen Kjp","year":"2024","journal-title":"CHEST Pulm"},{"key":"2026093013535453600_aaoag095-B28","doi-asserted-by":"publisher","first-page":"00111","DOI":"10.1183\/23120541.00111-2025","article-title":"Exploring reduced pulmonary exacerbation rates in cystic fibrosis: a pandemic or modulator effect?","volume":"11","author":"Stephenson","year":"2025","journal-title":"ERJ Open Res"}],"container-title":["Annals of the American Thoracic Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/annalsats\/advance-article-pdf\/doi\/10.1093\/annalsats\/aaoag095\/68159944\/aaoag095.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/23\/10\/1466\/68159944\/aaoag095.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/23\/10\/1466\/68159944\/aaoag095.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:53:57Z","timestamp":1790790837000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/annalsats\/article\/23\/10\/1466\/8662549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,26]]},"references-count":28,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,4,26]]},"published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/annalsats\/aaoag095","relation":{},"ISSN":["2329-6933","2325-6621"],"issn-type":[{"value":"2329-6933","type":"print"},{"value":"2325-6621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,4,26]]}}}